Interleukin-based anti-cancer therapy: Interleukin-37 (IL-37) increases the expression of CCM/KRITI via down regulation of its target gene, 07/March/2015, 16.02

MiRNA-based therapy for cancer: MiRNA-139-5p suppresses the expression of RNA polymerase III via down regulation of its target gene, 07/March/2015, 15.59
March 7, 2015
MiRNA-based therapy for Human Cancer: MiRNA-106b~25 suppresses the expression of Tripeptidyl Peptidase 1 (TPP1) via down regulation of its target gene, 7/March/2015, 16.08
March 7, 2015
Show all

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Web: http://genomediscovery.org

Significance:  This study suggests, for the first time, Interleukin-37 (IL-37), by suppressing the expression of its target gene, it may increase the expression of tumor suppressor CCM/KRITI. Thus, pharmacological formulations encompassing “IL-37 or its activators”  can be used to inhibit the progression of human tumors.

CitationBoominathan, Interleukin-based anti-cancer therapy: Interleukin-37 (IL-37) increases the expression of CCM/KRITI via down regulation of its target gene, 07/March/2015,  16.02, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

Undisclosed information: How IL-37 increases the expression of tumor suppressor CCM/KRTI1

Amount: $ 300*

* Research cooperation

Comments are closed.